Entera Bio, a portfolio company of DNA Biomedical Solutions Ltd. (TASE: DNA) located in Jerusalem, has announced the filing of a draft prospectus with the US Securities and Exchange Commission (SEC) for a Nasdaq IPO. Proceeds from the offering are for a trial of the company’s drug for treatment of Hypoparathyroidism. Hypoparathyroidism is an uncommon condition in which the body secretes abnormally low levels of parathyroid hormone (PTH). PTH is key to regulating and maintaining a balance of the body’s levels of two minerals — calcium and phosphorus.

The amount to be raised in the offering, probably in the tens of millions of dollars, will be used to pay for Phase II/III trials for Entera Bio’s drug for treatment of orphan disease Hypoparathyroidism. Since the disease is an orphan disease, the amount raised may be enough to complete the trial.

Oramed (Nasdaq: ORMD) has a 6% stake, because the original technology used in Entera Bio’s product was developed at Oramed.

See the full article in Globes:   http://www.globes.co.il/en/article-entera-bio-files-for-nasdaq-ipo-1001197354

See Entera Bio’s site: http://www.enterabio.com/